SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (6308)5/10/2002 10:40:02 AM
From: Ian@SI  Read Replies (1) | Respond to of 52153
 
You jumped the gun on VPHM. There will be another selloff when the FDA rejection gets documented in the 10Q! ;-) And then another one a few weeks later when some reporter takes the 10Q statement and reports it as "new" news.

The constant press on rising drug costs, reticence by Medicare/Medicaid to cover new drugs and the resultant slow uptake on new treatments such as Xigris certainly isn't helping the sector.

But this too, shall pass.

I hope. <g>

Ian



To: Biomaven who wrote (6308)5/10/2002 12:41:48 PM
From: aknahow  Read Replies (1) | Respond to of 52153
 
Peter, why do you consider the Amevive meeting too close to call? Certainly seems safer than existing treatments.

<<<I figure Amevive and Flumist are both too close to call.>>>



To: Biomaven who wrote (6308)5/12/2002 9:35:44 AM
From: jayhawk969  Respond to of 52153
 
Peter,

But until the NASD recovers I don't see much in the way of recovery for biotech stock prices either.

If the following has any truth we are in for a long haul.

zealllc.com


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News